results
Last reviewed 01/2018
There was no significant difference between patients treated with the experimental therapy of paclitaxel plus carboplatin and control treatments over a median follow-up period of 51 months. There was no significant difference in the occurrence of the secondary endpoint of progression-free survival.
There were differences in side-effect profiles:
- paclitaxel plus carboplatin caused more alopecia, fever and sensory neuropathy than carboplatin alone
- paclitaxel plus carboplatin caused more sensory neuropathy than CAP
- CAP caused more fever than paclitaxel plus carboplatin